Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D003606:Dacarbazine / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011183:Postoperative Complications
D001500:BCG Vaccine; D003606:Dacarbazine